At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 33 enrolled
Drug / intervention
dovitinib +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Study of TKI258 (Dovitinib) in Patients With Recurrent or Progressive Glioblastoma Who Have Progressed With or Without Anti-Angiogenic Therapy (Including Anti-VEGF Therapy)
In Brief
A Phase 2 clinical trial evaluating dovitinib and laboratory biomarker analysis for Adult Giant Cell Glioblastoma and 3 related conditions. Completed, enrolled 33 participants across 1 site.
Detailed Summary
This phase II trial studies how well dovitinib works in treating patients with recurrent or progressive glioblastoma. Dovitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Recurrent Adult Brain Tumor
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI), Novartis
Timeline
Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedDec 2012
Enrollment StartDec 2012
Primary CompletionJan 2015
Study CompletionSep 2017
TodayJul 2026
First PostedDec 20, 2012
Enrollment StartDec 20, 2012
Primary CompletionJan 28, 2015
Study CompletionSep 20, 2017
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 13.5 years ago
Interventions
dovitinibdrug
Given PO
laboratory biomarker analysisother
Correlative studies